John F. Seymour
Mary Baldwin University(US)The Royal Melbourne Hospital(AU)The University of Melbourne(AU)University of Melbourne(AU)Parks Victoria(AU)Peter MacCallum Cancer Centre(AU)Düsseldorf University Hospital(DE)Integrated Oncology (United States)(US)Mayo Clinic in Arizona(US)Mayo Clinic Hospital(US)University Hospital Cologne(DE)Melbourne Health(AU)Heinrich Heine University Düsseldorf(DE)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Viral-associated cancers and disorders
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study(2009)2,624 cited
- → Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia(2015)1,861 cited
- → iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL(2018)1,646 cited
- → The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee(2022)1,387 cited
- → International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts(2015)1,137 cited